瑞迪博士实验室
RDY
13.07
+0.17
+1.32%
瑞迪博士实验室
US · RDY
#1451 按市值排名
上市于 1970
13.07
+0.17
+1.32%
实时 - 追踪5344个代码 - 心跳于531秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了6家。
- 机构持股总比例下降了2.7个百分点。
机构持股
- 机构持股比例
- 60.25% -2.71pp
- 机构数量
- 402 -6
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund40.97%
Individual/Insider26.73%
Public Company13.12%
Hedge Fund2.37%
Private Company1.00%
Sovereign Wealth Fund0.85%
Government Pension Fund0.78%
Government0.64%
Corporate Pension Plan0.29%
Other13.26%
主要股东 截至 2026-03-31
Kallam Reddy
13.61% · 113.38M 股
Gunupati Prasad
13.07% · 108.91M 股
Life Insurance Corporation of India
12.19% · 101.50M 股
ICICI Prudential Asset Management Company Limited
5.05% · 42.05M 股
BlackRock
4.03% · 33.56M 股
Vanguard Capital Management, LLC
3.11% · 25.92M 股
PPFAS Asset Management Private Limited
2.91% · 24.23M 股
Boston Partners Global Investors, Inc.
2.17% · 18.04M 股
RBC Global Asset Management Inc.
1.88% · 15.68M 股
Nippon Life India Asset Management Limited
1.79% · 14.88M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪10份申报 · 0次买入 · 2次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Kallam Reddy | Chairman of the Board & Member of the Management Council | 13.61% |
| Gunupati Prasad | Co-Chairman, MD & Member of Management Council | 13.07% |
| Deepak Sapra | CEO of API & Services & Member of Management Council | 0.01% |
| Motupalli Ramana | CEO of Branded Markets - India & Emerging Countries and Member of Management Council | 0.01% |
| Milan Kalawadia | Chief Commercial Officer of North America Generics | 0.01% |
| M S Sundar | Head of Global Manufacturing FTO Oral Solid Dosages & Operational Excellence | 0.00% |
| Bhethanabottla Phanimitra | Chief Information Officer & Member of the Management Council | 0.00% |
| Sushrut Kulkarni | Global Head of Integrated Product Development Organisation & Member of the Management Council | 0.00% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-03-31 | M S Sundar | Head of Global Manufacturing FTO Oral Solid Dosages & Operational Excellence | Initial Statement of Beneficial | 0 | -- |
| 2025-12-17 | Gunupati Prasad | Co-Chairman, MD & Member of Management Council | Initial Statement of Beneficial | 0 | -- |
| 2025-12-17 | Kallam Reddy | Chairman of the Board & Member of the Management Council | Initial Statement of Beneficial | 0 | -- |
| 2025-12-17 | Deepak Sapra | CEO of API & Services & Member of Management Council | Initial Statement of Beneficial | 0 | -- |
| 2025-12-17 | Motupalli Ramana | CEO of Branded Markets - India & Emerging Countries and Member of Management Council | Initial Statement of Beneficial | 0 | -- |
| 2025-12-17 | Milan Kalawadia | Chief Commercial Officer of North America Generics | Initial Statement of Beneficial | 0 | -- |
| 2025-12-17 | Sushrut Kulkarni | Global Head of Integrated Product Development Organisation & Member of the Management Council | Initial Statement of Beneficial | 0 | -- |
| 2025-12-17 | Bhethanabottla Phanimitra | Chief Information Officer & Member of the Management Council | Initial Statement of Beneficial | 0 | -- |
| 2024-07-28 | Erez Israeli | CEO & Member of the Management Council | Intent to Sell (Form 144) | -327,500 | $16.46 |
| 2023-10-29 | Erez Israeli | CEO & Member of the Management Council | Intent to Sell (Form 144) | -25,000 | $13.09 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
瑞迪博士实验室 讨论区 0 条评论